ACI-7104.056
AssetVaccineAlso ACI-7104
Active immunotherapy eliciting an antibody response against pathological alpha-synuclein aggregates.
- Stage
- Phase 2
- Modality
- Vaccine
- Target
- SNCA
- Indications
- 2
- Trials
- 1
- Developers
- 1
Indications
2Early-onset Parkinson disease 6
Phase 2ACTIVE_NOT_RECRUITINGNCT06015841clinicaltrials.gov7 Oct 2026
Parkinson's disease
Phase 2ACTIVE_NOT_RECRUITINGNCT06015841clinicaltrials.gov7 Oct 2026
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors12
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 2 sources